Literature DB >> 20359166

Combined comparative and chemical proteomics on the mechanisms of levo-tetrahydropalmatine-induced antinociception in the formalin test.

Chen Wang1, Jiangrui Zhou, Shuowen Wang, Mingliang Ye, Chunlei Jiang, Guorong Fan, Hanfa Zou.   

Abstract

This study investigated the mechanisms involved in the antinociceptive action induced by levo-tetrahydropalmatine (l-THP) in the formalin test by combined comparative and chemical proteomics. Rats were pretreated with l-THP by the oral route (40 mg/kg) 1 h before formalin injection. The antinociceptive effect of l-THP was shown in the first and second phases of the formalin test. To address the mechanisms by which l-THP inhibits formalin-induced nociception in rats, the combined comparative and chemical proteomics were applied. A novel high-throughput comparative proteomic approach based on 2D-nano-LC-MS/MS was applied to simultaneously evaluate the deregulated proteins involved in the response of l-THP treatment in formalin-induced pain rats. Thousands of proteins were identified, among which 17 proteins survived the stringent filter criteria and were further included for functional discussion. Two proteins (Neurabin-1 and Calcium-dependent secretion activator 1) were randomly selected, and their expression levels were further confirmed by Western Blots. The results matched well with those of proteomics. In the present study, we also described the development and application of l-THP immobilized beads to bind the targets. Following incubation with cellular lysates, the proteome interacting with the fixed l-THP was identified. The results of comparative and chemical proteomics were quite complementary. Although the precise roles of these identified moleculars in l-THP-induced antinociception need further study, the combined results indicated that proteins associated with signal transduction, vesicular trafficking and neurotransmitter release, energy metabolism, and ion transport play important roles in l-THP-induced antinociception in the formalin test.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20359166     DOI: 10.1021/pr1001274

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  6 in total

1.  Studies on the analgesic activities of Jia-Yuan-Qing pill and its safety evaluation in mice.

Authors:  Ye Tian; Li-rong Teng; Jing-jing Song; Qing-fan Meng; Jia-hui Lu; Wei-wei Zhang; Kang Wei; Ning Wang; Di Wang; Le-sheng Teng
Journal:  Protoplasma       Date:  2014-03-28       Impact factor: 3.356

Review 2.  Role of natural products in mitigation of toxic effects of methamphetamine: A review of in vitro and in vivo studies.

Authors:  Mohammad Moshiri; Ali Roohbakhsh; Mahdi Talebi; Milad Iranshahy; Leila Etemad
Journal:  Avicenna J Phytomed       Date:  2020 Jul-Aug

3.  Astragaloside IV Attenuates Glutamate-Induced Neurotoxicity in PC12 Cells through Raf-MEK-ERK Pathway.

Authors:  Rongcai Yue; Xia Li; Bingyang Chen; Jing Zhao; Weiwei He; Hu Yuan; Xing Yuan; Na Gao; Guozhen Wu; Huizi Jin; Lei Shan; Weidong Zhang
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

4.  Antinociceptive Profile of Levo-tetrahydropalmatine in Acute and Chronic Pain Mice Models: Role of spinal sigma-1 receptor.

Authors:  Dong-Wook Kang; Ji-Young Moon; Jae-Gyun Choi; Suk-Yun Kang; Yeonhee Ryu; Jin Bong Park; Jang-Hern Lee; Hyun-Woo Kim
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

5.  Levo-tetrahydropalmatine inhibits α4β2 nicotinic receptor response to nicotine in cultured SH-EP1 cells.

Authors:  Yuan-Bing Huang; Ze-Gang Ma; Chao Zheng; Xiao-Kuang K Ma; Devin H Taylor; Ming Gao; Ronald J Lukas; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2021-07-12       Impact factor: 6.150

6.  Levo-Tetrahydropalmatine Attenuates Bone Cancer Pain by Inhibiting Microglial Cells Activation.

Authors:  Mao-Yin Zhang; Yue-Peng Liu; Lian-Yi Zhang; Dong-Mei Yue; Dun-Yi Qi; Gong-Jian Liu; Su Liu
Journal:  Mediators Inflamm       Date:  2015-12-27       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.